Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > SBM still tweeting!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Comment by Mickey2on Mar 01, 2021 10:09am
135 Views
Post# 32684629

RE:RE:RE:SBM still tweeting!

RE:RE:RE:SBM still tweeting!not $40 but i'll take $1 John.

pointer wrote:
Pareto8020 wrote: If all these tweets aren't a run up to an imminent release of news such as a March 9th TFC-1067 R&F product launch or Wanbang finally releasing Phase 1 results any credibility SBM and Howard currently hold will evaporate along with shareholders.

I think 2021 is finally the year SBM takes off though - too many irons in the fire for a long time now for one or more of them not to pay off.  Plus the science and technology is proven to be valid and have commercial value.


If R&F doesn't launch TFC1067 on March 9, I think we might have a case for ousting the entire SBM management for intentionally misleading shareholders.

But, like you, I think it is happening. R&F provide the initial push back to old highs, then one of the many other targets gets hit, and the market really begins to take notice.

I am not saying we go from 40 cents to 40 dollars, but I have seen it happen before. :o)


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities